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Abstract
Background:  Bone gamma-carboxyglutamate protein (BGLAP; osteocalcin) is a small, highly
conserved molecule first identified in the mineralized matrix of bone. It has been implicated in the
pathophysiology of various malignancies. In this study, we analyzed the expression and role of
BGLAP in the normal human pancreas, chronic pancreatitis (CP), and pancreatic ductal
adenocarcinoma (PDAC) using quantitative RT-PCR, immunohistochemistry,
immunocytochemistry and enzyme immunoassays, as well as cell proliferation and invasion assays.
Gene silencing was carried out using specific siRNA molecules.
Results:  Compared to the normal pancreas, BGLAP mRNA and protein levels were not
significantly different in CP and PDAC tissues. BGLAP was faintly present in the cytoplasm of
normal acinar cells but was strongly expressed in the cytoplasm and nuclei of tubular complexes
and PanIN lesions of CP and PDAC tissues. Furthermore, BGLAP expression was found in the
cancer cells in PDAC tissues as well as in 4 cultured pancreatic cancer cell lines. TNFalpha reduced
BGLAP mRNA and protein expression levels in pancreatic cancer cell lines. In addition, BGLAP
silencing led to reduction of both cell growth and invasion in those cells.
Conclusion:  BGLAP is expressed in pancreatic cancer cells, where it potentially increases
pancreatic cancer cell growth and invasion through autocrine and/or paracrine mechanisms.
Introduction
Bone gamma-carboxyglutamic acid protein (BGLAP or
osteocalcin) is a small, highly conserved molecule associ-
ated with mineralization of bone matrix [1]. BGLAP is an
11 kDa protein which is synthesized and secreted by nor-
mal maturing osteoblasts [2]. It regulates the dynamics of
new bone formation and bone resorption [3-5] by inter-
action with vitamin D, and by influencing the differentia-
tion of osteoblasts [6-8]. BGLAP is also involved in the
posttranslational targeting of vitamin K-dependent
gamma-carboxylation [1], which controls blood coagula-
tion. Accordingly, defects in BGLAP expression lead to the
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development of chondrodysplasia punctata, coagulation
defects, and coumarin embryopathy [9]. Since the discov-
ery of BGLAP secretion in a subset of osteosarcoma cell
lines [10], BGLAP has been implicated in the develop-
ment of various malignant tumors. In multiple myeloma,
BGLAP is considered a biochemical marker for bone
resorption and dynamics during the malignant process.
Thus, serum BGLAP levels are reduced in patients with
multiple myeloma with osteolytic bone lesions [11].
There is also growing evidence that markers of bone
metabolism correlate with the risk of skeletal complica-
tions, disease progression and tumor growth [12,13]. In
prostate cancer, BGLAP is expressed in the cancer cells and
improves adhesion, proliferation, and survival of tumor
cells metastasizing to the bone [14]. In breast cancer,
BGLAP serum levels determine the progress of the disease,
especially with respect to bone metastases [15,16].
Although metastasis of pancreatic cancer to the bones is
exceedingly rare, both PDAC and CP are characterized by
a dense desmoplastic reaction, which in the case of CP
often leads to calcification. Therefore, in the present study
we analyzed the expression of BGLAP in normal and dis-
eased human pancreatic tissues.
Results
To exactly quantify mRNA levels of BGLAP in bulk pancre-
atic tissues, qRT-PCR was carried out. This analysis dem-
onstrated no significant difference between median
BGLAP mRNA levels in the normal pancreas, CP and
PDAC tissues (figure 1A). As the cellular composition of
bulk PDAC and CP tissues is different than that of normal
pancreatic tissues, BGLAP mRNA values were normalized
to amylase-2A (Amy2A) mRNA levels for each tissue sam-
ple to exclude the mRNA expression of BGLAP in the acini
(figure 1B). This analysis revealed a significant increase in
the mRNA ratio of BGLAP/Amy2A in PDAC (p < 0.0001)
compared to normal pancreatic tissues. This suggests that
in PDAC, tissue elements other than acini contribute to
the observed BGLAP mRNA levels in bulk tissues. There-
fore, and in order to localize BGLAP, immunohistochem-
istry was performed on pancreatic tissue sections from
normal (n = 10), CP (n = 20) and PDAC (n = 20) cases.
BGLAP expression was weak to absent in normal pancre-
atic ductal cells of 9/10 normal pancreatic tissues (figure
2A). In contrast, acinar cells of 9/10 normal pancreatic tis-
sues exhibited moderate cytoplasmic BGLAP staining (fig-
ure 2A). PanIN1-2 lesions in normal pancreatic tissues
demonstrated weak to moderate BGLAP staining (figure
2B). In contrast, in CP tissues there was moderate cyto-
plasmic and occasionally nuclear staining of tubular com-
plexes in 18 out of 20 cases (figure 2C). Moderate BGLAP
staining was also observed in the PanIN1-2 lesions (figure
2D), as well as in ductal cells (figure 2E &2F). In 15/20
PDAC tissues, moderate to strong cytoplasmic and occa-
sionally nuclear BGLAP staining was observed in the tubu-
lar complexes (figure 3A &3B), PanIN1-3 lesions (figure
3C &3D), and cancer cells (figure 3E). The specificity of
the staining was confirmed using normal mouse IgG as a
negative control in consecutive sections (figure 3F).
Next, BGLAP serum levels were determined in CP and
PDAC patients and compared to healthy volunteers. This
analysis revealed a significant reduction in BGLAP serum
levels in PDAC patients (figure 4; p < 0.05). There was no
significant difference between CP and PDAC serum
BGLAP levels. Correlation analysis of BGLAP mRNA and
serum levels with clinico-pathological parameters of
PDAC patients revealed no significant difference in the
median BGLAP mRNA or serum levels in PDAC patients
with lymph node metastasis compared to PDAC patients
Expression of BGLAP in pancreatic tissues Figure 1
Expression of BGLAP in pancreatic tissues. Quantita-
tive RT-PCR analysis of mRNA levels for BGLAP in normal 
pancreatic, CP and PDAC tissue samples was carried out as 
described in the Methods section before (A) and after (B) 
normalization to Amy2A. RNA input was normalized to the 
average expression of the two housekeeping genes HPRT 
and cyclophilin B, and is presented as adjusted transcripts/
10,000 CPB copies.
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without lymph node metastasis (p = 0.9; data not shown).
There was also no correlation with other parameters such
as tumor size or grade.
In a subsequent step, the expression of BGLAP was deter-
mined in Aspc-1, Capan-1, Panc-1 and T3M4 cultured
pancreatic cancer cells. BGLAP mRNA was detected in
these cell lines with a range of 73–254 copies/10,000 CPB
copies (figure 5A). In addition, BGLAP protein was
detected in the cell culture supernatants of the same four
cell lines by EIA, where the range of BGLAP expression
was 3.4 to 4 ng/ml (figure 5B). BGLAP was present in the
cytoplasm and occasionally in the nuclei of pancreatic
cancer cell lines as determined in the four cultured pancre-
atic cancer cell lines by immunocytochemistry (figure 5B).
Since BGLAP was expressed in pancreatic cancer tissues
and cells, various growth factors that might be involved in
pancreatic carcinogenesis were examined for their effect
on BGLAP expression. Aspc-1, Capan-1, Panc-1 and T3M4
pancreatic cancer cells were treated with recombinant
TGF-β1, BMP2, FGF2, Shh, Ihh and TNF-α for 48 h as
described previously [17]. Of those cytokines, only TNF-α
was able to moderately but consistently reduce BGLAP
mRNA and protein levels in the four cultured pancreatic
cancer cell lines (figure 6A &6B). The maximum effects
were observed in Aspc-1, where BGLAP mRNA and pro-
Localization of BGLAP in normal pancreatic and CP tissues by immunohistochemistry Figure 2
Localization of BGLAP in normal pancreatic and CP tissues by immunohistochemistry. Immunohistochemistry 
was performed using a specific BGLAP antibody as described in the Methods section. BGLAP was localized in the cytoplasm of 
the normal acinar cells but not in the normal ducts (A), and weakly localized in the PanIN1-2 lesions (B). In CP tissues, BGLAP 
was localized in the cytoplasm of the cells of the tubular complexes (C), PanIN1-2 lesions (D) and large ducts (E & F). Insets 
show high magnification of structures indicated by arrows. A magnification scale bar of 100 μm is shown.
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tein levels were reduced by -32.3 +/- 7.9% and -38.8 +/-
2% (p < 0.01), respectively. The other cytokines demon-
strated no significant effects on BGLAP expression in the
tested pancreatic cancer cells (data not shown).
In order to determine the role of BGLAP in regulating the
growth and invasion of pancreatic cancer cells, BGLAP
was silenced using siRNA molecules in Aspc-1 and Panc-1
pancreatic cancer cells. BGLAP silencing effects (-17 +/-
2.3% and -15.3 +/- 6.3%) (p < 0.05) were detected by EIA
in cell culture supernatant of both Aspc-1 and Panc-1
cells, respectively (figure 7A). After BGLAP silencing, cell
growth and invasion assays were carried out. Both Aspc-1
and Panc-1 cells exhibited a reduction in cell growth (-
22.8 +/- 1.8% and -25.1 +/- 2.4% [p < 0.05], respectively)
compared to cells transfected with control siRNA (figure
7B). In addition, both Aspc-1 and Panc-1 cells exhibited a
reduction in cell invasion (-29.3 +/- 1.5% and -30.2 +/-
3% [p < 0.05], respectively) compared to cells transfected
with control siRNA (figure 7C).
Discussion
BGLAP is a small protein (10.9 kDa) [2] that is secreted by
osteosarcoma cells [10] and is involved in bone turn-over
of metastatic lesions from tumors such as prostate and
breast cancers. In the present study, BGLAP mRNA levels
were not significantly different between bulk normal pan-
creatic, CP and PDAC tissues. Normal pancreatic tissues
consist mainly of acinar cells (and to a lesser extent of
islets and ductal cells). In contrast, in CP tissues, the aci-
Localization of BGLAP in PDAC tissues by immunohistochemistry Figure 3
Localization of BGLAP in PDAC tissues by immunohistochemistry. Immunohistochemistry was performed using a 
specific BGLAP antibody as described in the Methods section. BGLAP exhibited a cytoplasmic and occasionally nuclear localiza-
tion high-grade PanIN lesions (A & B) and cancer cells (C-E). The specificity of the staining was performed using control IgG 
(F). Insets show high magnification of structures indicated by arrows. A magnification scale bar of 100 μm is shown.
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nar cell compartment is replaced by extensive fibrosis,
ductal proliferation, and acinar cell conversion into tubu-
lar complexes [18-21]. These changes further progress
towards malignant transformation and cancer cell prolif-
eration in PDAC [19,22]. In the present study, BGLAP was
localized in the acini of normal pancreatic tissues, indicat-
ing that the mRNA content of BGLAP represents the acinar
fraction in normal pancreatic tissues. Interestingly,
BGLAP was localized in the tubular complexes and PanIN
lesions of both CP and PDAC as well as in the cancer cells
in PDAC. This was indirectly confirmed by normalizing
BGLAP mRNA levels to the acinar marker Amy2A. Using
this method, a significant increase in the ratio of BGLAP/
Amy2A mRNA expression in PDAC tissues was observed
compared to normal pancreatic tissues. This might indi-
cate that BGLAP is expressed in the disease-specific tissue
elements such as the tubular complexes, PanINs and can-
cer cells. Surprisingly, there was a decrease of BGLAP
serum levels in PDAC patients compared to healthy con-
trols. These findings suggest that BGLAP is principally
released by acinar cells in the normal and diseased pan-
creas. However, since cytoplasmic expression of BGLAP
was also observed in tubular complexes and cancer cells,
it could be speculated that BGLAP is not efficiently
released from these cells. This might explain the elevated
BGLAP serum levels in healthy controls despite similar
amounts of BGLAP mRNA in bulk diseased pancreatic tis-
sues.
Numerous growth factors and cytokines – such as TGF-β1
[23,24], BMP2 [25], FGF2 [26], Shh [27], Ihh [28] and
TNF-α [29] – have been implicated in the pathogenesis of
PDAC. Among those factors, only TNF-α reduced the
expression of BGLAP in pancreatic cancer cell lines. The
other growth factors and cytokines exhibited no effects on
Expression and localization of BGLAP in four cultured pan- creatic cancer cell lines Figure 5
Expression and localization of BGLAP in four cul-
tured pancreatic cancer cell lines. (A) QRT-PCR analysis 
of mRNA levels for BGLAP in pancreatic cancer cells was 
carried out as described in the Methods section. RNA input 
was normalized to the average expression of the two house-
keeping genes HPRT and cyclophilin B. Bars represent the 
mean values +/- SEM of 3 independent experiments as 
adjusted transcripts/10,000 CPB copies. (B) Enzyme immu-
noassay of BGLAP levels in cell culture supernatant of pan-
creatic cancer cell lines was carried out as described in the 
Methods section. Bars represent the mean values +/- SEM of 
3 independent experiments in ng/ml. Localization of BGLAP 
in the cultured pancreatic cancer cell lines was performed by 
immunocytochemistry as described in the Methods section, 
using a specific BGLAP antibody (+). The specificity of the 
staining was confirmed using control IgG (-).
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Enyzme immunoassay of tissue samples Figure 4
Enyzme immunoassay of tissue samples. Enzyme 
immunoassay of BGLAP levels in normal pancreatic, CP and 
PDAC tissue samples was carried out as described in the 
Methods section. Horizontal bars represent median values.
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BGLAP expression in the tested pancreatic cancer cells.
TNF-α has anti-tumor effects in pancreatic adenocarci-
noma [29-31]. The down-regulation of BGLAP by TNF-α
in pancreatic cancer cells indicates that BGLAP is one of
the TNF-α targets and indirectly suggests a tumor-promot-
ing function of BGLAP in pancreatic cancer. In line with
this argument, down-regulation of BGLAP levels using
siRNA molecules resulted in a significant reduction in
pancreatic cancer cell growth and invasion. This has also
been shown in other tumors, such as osteosarcoma
[32,33].
The transcription of BGLAP is dependent on the expres-
sion of runx2 transcription factor, which binds to an oste-
oblast-specific cis-acting element in the promoter of
BGLAP [34]. Runx2 is over-expressed in PDAC [17], and
other factors downstream of runx2, such as osteopontin
[35] and SPARC [36], are also over-expressed in PDAC
and have the potential to increase pancreatic cancer inva-
sion and metastasis [37,38]. In contrast, runx2 represses
the expression of bone sialoprotein [39], which is only
weakly expressed in pancreatic cancer cells [39].
The effects of BGLAP silencing on pancreatic cancer cell  growth and invasion Figure 7
The effects of BGLAP silencing on pancreatic cancer 
cell growth and invasion. (A) Aspc-1 and Panc-1 pancre-
atic cancer cells were subjected to BGLAP silencing using 
two different specific BGLAP siRNA molecules, and the 
effects of silencing were measured by enzyme immunoassay 
as described in the Methods section. (B) Cell growth and (C) 
invasion assays were performed as described in the Methods 
section. Data are presented as mean +/- SEM compared to 
the respective controls of three independent experiments (*: 
p < 0.05).
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Effects of TNF-α on BGLAP expression in pancreatic cancer  cells Figure 6
Effects of TNF-α on BGLAP expression in pancreatic 
cancer cells. (A) Pancreatic cancer cells were treated with 
the indicated dose of TNF-α for 48 h. Cell lysates and cell 
culture supernatants were collected for detection of BGLAP 
mRNA and protein expression, respectively, as described in 
the Methods section. Bars represent BGLAP mRNA (A) and 
protein expression levels (B) as a percentage of untreated 
cells and as determined by QRT-PCR and enzyme immu-
noassay, respectively. Data are presented as mean +/- SEM of 
three independent experiments (*: p < 0.05, **: p < 0.01).
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Conclusion
In conclusion, BGLAP is expressed in the tubular com-
plexes and cancer cells of CP and PDAC tissues and has
the potential to increase pancreatic cancer cell growth and
invasion.
Materials and methods
Tissue and serum sampling
Pancreatic tissue specimens were obtained from 20 CP
and 20 PDAC patients with a median age of 62.5 years
(range: 41–78 years) in whom pancreatic resections were
performed. Normal human pancreatic tissue samples
were obtained through an organ donor program from 10
previously healthy individuals (median age: 45 years;
range: 18–76 years). For all samples, the diagnosis was
confirmed histologically. Freshly removed tissues (within
5 min after surgical excision) were: a) fixed in paraformal-
dehyde solution for 12 to 24 h and then paraffin embed-
ded for histological analysis; b) kept in RNAlater (Ambion
Ltd., Huntingdon, Cambridgeshire, United Kingdom) for
RNA analysis, or c) snap-frozen in liquid nitrogen and
maintained at -80°C for protein analysis. Serum samples
were obtained from 87 PDAC patients (median age: 63
years) and 36 CP patients (median age: 50 years). Forty
serum samples were obtained from healthy volunteers
(median age: 35 years). Fresh blood samples were col-
lected and centrifuged. The serum supernatant was col-
lected in polyethylene tubes and kept frozen at -80°C
until use. The Human Ethics Committee of the University
of Heidelberg, Germany, approved all studies, and written
informed consent was obtained from all patients.
Cell culture
ASPC-1, Capan-1, and T3M4 pancreatic cancer cells were
routinely grown in RPMI 1640 medium (Life Technolo-
gies, Karlsruhe, Germany), supplemented with 10% FCS
(Sigma-Aldrich, St. Louis, MO) and 100 U/ml penicillin/
streptomycin (Invitrogen GmbH, Karlsruhe, Germany).
Panc-1 was routinely grown in DMEM medium (Invitro-
gen), supplemented with 10% FCS and 100 U/ml penicil-
lin/streptomycin. For induction experiments, cells were
seeded in 10 cm cell culture plates in 10% FCS growth
medium and allowed to attach for 12 h. Growth medium
was replaced by serum-reduced medium (1% FCS), and
supplemented with recombinant TGF-β1 (500 pM),
BMP2 (100 ng/ml) bFGF2 (10 ng/ml), sonic hedgehog
(Shh) (500 ng/ml), indian hedgehog (Ihh) (500 ng/ml)
(all from R&D Systems GmbH, Wiesbaden, Germany) or
TNF-α (100 ng/ml; Promega Biosciences Inc., Mannheim,
Germany) for 48 h. Afterwards, cell culture supernatants
and mRNA were collected as described.
Immunohistochemistry
Immunohistochemistry was performed as previously
described [40] with slight modifications. Consecutive 5
μm-thick paraffin-embedded tissue sections were depar-
affinized and rehydrated in progressively decreasing con-
centrations of ethanol. After antigens were retrieved by
boiling the tissue sections in 10 mM citrate buffer for 10
min in the microwave oven, endogenous peroxidase activ-
ity was quenched by incubation in deionized water con-
taining 3% hydrogen peroxide at room temperature for 10
min. The slides were then washed in washing buffer (10
mM Tris-HCl, 0.85% NaCl, 0.1% bovine serum albumin,
and pH 7.4), and incubated with the mouse monoclonal
BGLAP antibody (ZYTOMED Systems GmbH, Berlin, Ger-
many) diluted in a universal block reagent (DAKO Corpo-
ration, Carpentaria, CA) for 18 h at 4°C. In consecutive
sections, the specificity of the primary antibody was con-
firmed using the corresponding normal mouse IgG
(DAKO). The slides were then rinsed with washing buffer
and incubated with anti-mouse HRPO-labeled IgG
(Amersham International, Buckinghamshire, UK) diluted
in a universal blocking reagent (DAKO) for 1 h at room
temperature. The tissue sections were then washed in
washing buffer and each section was subjected to 100 μl
of DAB-chromogen/substrate reagent (DAKO) and coun-
terstained with Mayer's hematoxylin.
Immunocytochemistry was performed as described previ-
ously [41]. Briefly, pancreatic cancer cells were cultured
on Super Frost microscope slides (Menzel GmbH & Co
KG, Braunschweig, Germany) overnight till adherent and
then washed with phosphate buffered saline (PBS), fixed
with 3.5% para-formaldehyde for 25 min, and quenched
with 30 mM glycine/PBS for 5 min, followed by permea-
bilization of the cell membrane with 0.1% Triton x-100
for 5 min at room temperature. Next, slides were incu-
bated with the mouse monoclonal BGLAP antibody and
immunostaining was performed as described above.
Slides were analyzed using the Axioplan 2 imaging micro-
scope (Carl Zeiss light microscope, Göttingen, Germany).
Enzyme immunoassay (EIA)
Determination of the BGLAP protein levels was per-
formed with an enzyme immunoassay (EIA) kit (Takara
Bio Inc., Shiga, Japan). Briefly, 96-well flat-bottomed
plates pre-coated with the mouse monoclonal BGLAP
antibody were loaded with 100 μl serum, cell culture
supernatant or protein standards for 2 h at room temper-
ature. After washing with PBS, 100 μl of the BGLAP anti-
body labeled with peroxidase (POD) were loaded into the
wells for 1 h at room temperature. Next, 100 μl of sub-
strate solution were added to the wells for 20 min at room
temperature, followed by the addition of 100 μl 1N
H2SO4 stop solution. Then, absorbance was measured at
450 nm using a microtiter plate reader (Opsys MR,
Thermo Labsystems, Frankfurt, Germany).Molecular Cancer 2007, 6:83 http://www.molecular-cancer.com/content/6/1/83
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siRNA transfection
Aspc-1 and Panc-1 pancreatic cancer cells were grown in
complete RPMI or DMEM medium in 10 ml cell culture
plates until 50% confluence. BGLAP siRNA transfection
was performed using RNAifect transfection reagent (Qia-
gen, Hilden, Germany) according to the manufacturer's
instructions. Cells were transfected with a 5 μg mixture of
two BGLAP siRNA target sequences – Hs-BGLAP-3-HP
siRNA (AAG CAG GAG GGC AGC GAG GTA) and Hs-
BGLAP-4-HP siRNA (CCC AGG CGC TAC CTG TAT CAA)
– as well as with a control siRNA target sequence (AAT
TCT CCG AAC GTG TCA CGT) (Qiagen, Hilden, Ger-
many) for 48 h.
Cell growth assays
Aspc-1 and Panc-1 pancreatic cancer cells transfected with
BGLAP siRNAs or control siRNA were seeded at a density
of 5000 cells/well in 96-well plates for 48 h. Then, 10 ml
MTT (5 mg/ml) dissolved in PBS pH 7.4 were added to
each well and incubated for 4 h at 37°C. Subsequently,
cellular formazan crystals were solubilized with 0.04 mM
HCl/isopropanol. Optical density was measured at 570
nm with an ELISA plate reader (Opsys MR). All assays
were performed in triplicate.
In vitro invasion assays
The Matrigel invasion assay (BD Biosciences, Heidelberg,
Germany) was used to assess the invasive potential of
pancreatic cancer cells following BGLAP silencing. Briefly,
BioCoat Matrigel invasion chambers were rehydrated
according to the manufacturer's instructions. Five hun-
dred μl of DMEM cell culture medium supplemented with
10% FCS were added to the bottom of 24-well plates.
Aspc-1 and Panc-1 pancreatic cancer cells transfected with
BGLAP siRNAs or control siRNA were seeded at a density
of 50,000 cells/well into the upper inserts and incubated
at 37°C. After 24 h, the non-invading cells were removed
from the upper surface of the separating membrane by
gentle scrubbing with a cotton swab. Invading cells were
fixed in ice-cold 100% methanol and stained with 0.05%
crystal violet in 20% ethanol. The membranes were
mounted on glass slides and manually counted using a
light microscope. The invasion index was calculated as the
percentage of invading cells in the treatment group com-
pared to the control group. All assays were performed in
triplicate.
Statistical analysis
For statistical analyses, the non-parametric Mann-Whit-
ney test and the Kruskal-Wallis test (followed by Dunn's
post-hoc test) were used, unless indicated otherwise. Sig-
nificance was defined as p < 0.05.
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